Trial Profile
A Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks on Brain Tumor O-6-Methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.; Schering-Plough
- 27 Jan 2012 Actual end date changed from Jan 2011 to Feb 2011 as reported by ClinicalTrials.gov.
- 02 Feb 2011 Planned end date changed from 1 Mar 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 02 Feb 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.